{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:30Z","timestamp":1789001250436,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11060-021-03900-w","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T05:02:54Z","timestamp":1645592574000},"page":"225-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults"],"prefix":"10.1007","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-373X","authenticated-orcid":false,"given":"Isabelle M.","family":"Germano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Ziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ryan","family":"Ormond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"3900_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11060-013-1338-5","volume":"118","author":"JJ Olson","year":"2014","unstructured":"Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN (2014) The role of cytotoxic chemotherapy in the management of progressive glioblastoma. J Neurooncol 118:501\u2013555","journal-title":"J Neurooncol"},{"issue":"5","key":"3900_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung WK, Albright RE, Olson JJ et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Brit j cancer 83(5):588\u2013593","journal-title":"Brit j cancer"},{"issue":"8956","key":"3900_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","volume":"345","author":"H Brem","year":"1995","unstructured":"Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intra-operative controlled biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345(8956):1008\u20131012","journal-title":"Lancet"},{"issue":"10","key":"3900_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352(10):987\u2013996","journal-title":"New Engl J Med"},{"issue":"5","key":"3900_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459\u2013466","journal-title":"Lancet Oncol"},{"issue":"1","key":"3900_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1186\/s12885-016-2945-2","volume":"16","author":"ET Wong","year":"2016","unstructured":"Wong ET, Timmons J, Callahan A, O\u2019Loughlin L, Giarusso B, Alsop DC (2016) Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. BMC Cancer 16(1):914","journal-title":"BMC Cancer"},{"issue":"4","key":"3900_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/cns.14.29","volume":"3","author":"VA van Vugt","year":"2014","unstructured":"van Vugt VA, Piccioni DE, Brown BD et al (2014) Retrospective analysis of safety and feasibility of a 3 days on\/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. CNS Oncol 3(4):257\u2013265","journal-title":"CNS Oncol"},{"issue":"9","key":"3900_CR8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/neuonc\/nou044","volume":"16","author":"SJ Han","year":"2014","unstructured":"Han SJ, Rolston JD, Molinaro AM et al (2014) Phase II trial of 7 days on\/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol 16(9):1255\u20131262","journal-title":"Neuro Oncol"},{"issue":"2","key":"3900_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/neuonc\/nos295","volume":"15","author":"A Omuro","year":"2013","unstructured":"Omuro A, Chan TA, Abrey LE et al (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2):242\u2013250","journal-title":"Neuro Oncol"},{"key":"3900_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002262","volume":"3","author":"E Archavlis","year":"2013","unstructured":"Archavlis E, Tselis N, Birn G, Ulrich P, Baltas D (2013) Zamboglou N (2013) Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme. BMJ Open 3:e002262. https:\/\/doi.org\/10.1136\/bmjopen-2012-002262","journal-title":"BMJ Open"},{"issue":"7","key":"3900_CR11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/neuonc\/not040","volume":"15","author":"AD Norden","year":"2013","unstructured":"Norden AD, Lesser GJ, Drappatz J et al (2013) Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 15(7):930\u2013935","journal-title":"Neuro Oncol"},{"issue":"11","key":"3900_CR12","doi-asserted-by":"publisher","first-page":"e017387","DOI":"10.1136\/bmjopen-2017-017387","volume":"7","author":"SV Roussakow","year":"2017","unstructured":"Roussakow SV (2017) Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21\/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. BMJ open 7(11):e017387","journal-title":"BMJ open"},{"issue":"1","key":"3900_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2176\/nmc.oa.2016-0162","volume":"57","author":"T Aoki","year":"2017","unstructured":"Aoki T, Arakawa Y, Ueba T et al (2017) Phase I\/II study of temozolomide plus nimustine chemotherapy for recurrent malignant gliomas: Kyoto neuro-oncology group. Neurol Med Chir 57(1):17\u201327","journal-title":"Neurol Med Chir"},{"issue":"49","key":"3900_CR14","doi-asserted-by":"publisher","first-page":"e9053","DOI":"10.1097\/MD.0000000000009053","volume":"96","author":"L Wang","year":"2017","unstructured":"Wang L, Liang L, Yang T et al (2017) A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: clinical trial\/experimental study. Medicine 96(49):e9053","journal-title":"Medicine"},{"issue":"2","key":"3900_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CAD.0000000000000314","volume":"27","author":"G Reynes","year":"2016","unstructured":"Reynes G, Martinez-Sales V, Vila V et al (2016) Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. Anticancer Drugs 27(2):133\u2013137","journal-title":"Anticancer Drugs"},{"issue":"2","key":"3900_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11060-017-2537-2","volume":"134","author":"A Di Cristofori","year":"2017","unstructured":"Di Cristofori A, Zarino B, Fanizzi C et al (2017) Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. J Neurooncol 134(2):377\u2013385","journal-title":"J Neurooncol"},{"issue":"12","key":"3900_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/neuonc\/nos256","volume":"14","author":"E Franceschi","year":"2012","unstructured":"Franceschi E, Stupp R, van den Bent MJ et al (2012) EORTC 26083 phase I\/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol 14(12):1503\u20131510","journal-title":"Neuro Oncol"},{"issue":"27","key":"3900_CR18","doi-asserted-by":"publisher","first-page":"e11254","DOI":"10.1097\/MD.0000000000011254","volume":"97","author":"A Marinellli","year":"2018","unstructured":"Marinellli A, Cerbone L, Cordua N, Buonerba C, Peluso G, Di Lorenzo G, De Placido S (2018) High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I\/II trial. Medicine 97(27):e11254","journal-title":"Medicine"},{"issue":"1","key":"3900_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000464464","volume":"93","author":"J Klein","year":"2017","unstructured":"Klein J, Juratli TA, Radev Y et al (2017) Safety and effectiveness of bis-chloroethylnitrosourea wafer chemotherapy in elderly patients with recurrent glioblastoma. Oncology 93(1):43\u201350","journal-title":"Oncology"},{"issue":"8","key":"3900_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12094-015-1444-2","volume":"18","author":"P Perez-Segura","year":"2016","unstructured":"Perez-Segura P, Manneh R, Ceballos I et al (2016) GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clin Transl Oncol 18(8):805\u2013812","journal-title":"Clin Transl Oncol"},{"key":"3900_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11060-016-2136-7","volume":"128","author":"G Lombardi","year":"2016","unstructured":"Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D\u2019Avella D, Zagonel V (2016) Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. J Neurooncol 128:481\u2013486","journal-title":"J Neurooncol"},{"issue":"7\u20138","key":"3900_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000431236","volume":"38","author":"BF Carvalho","year":"2015","unstructured":"Carvalho BF, Fernandes AC, Almeida DS et al (2015) Second-line chemotherapy in recurrent glioblastoma: A 2-cohort study. Oncol Res Treat 38(7\u20138):348\u2013354","journal-title":"Oncol Res Treat"},{"key":"3900_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000360295","volume":"86","author":"F Mack","year":"2014","unstructured":"Mack F, Schafer N, Kebir S, Stuplich M, Schaub C, Niessen M, Scheffler B, Herrlinger U, Glas M (2014) Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma. Oncology 86:369\u2013372","journal-title":"Oncology"},{"key":"3900_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-013-1125-3","volume":"1113","author":"M Santoni","year":"2013","unstructured":"Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S (2013) Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol 1113:397\u2013401","journal-title":"J Neurooncol"},{"issue":"9","key":"3900_CR25","first-page":"4013","volume":"33","author":"F De Felice","year":"2013","unstructured":"De Felice F, Bulzonetti N, Musio D, D\u2019Elia A, Salvati M, Tombolini V (2013) Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme. Anticancer Res 33(9):4013\u20134016","journal-title":"Anticancer Res"},{"key":"3900_CR26","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315\u2013e329. https:\/\/doi.org\/10.1016\/S1470-2045(17)30194-8","journal-title":"Lancet Oncol"},{"key":"3900_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","volume":"24","author":"BM Alexander","year":"2018","unstructured":"Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM et al (2018) Adaptiveglobal innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res 24:737\u2013743. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0764","journal-title":"Clin Cancer Res"},{"key":"3900_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1534735418812691","author":"G Fiorentini","year":"2019","unstructured":"Fiorentini G, Sarti D, Milandri C, Dentico P, Mambrini A, Fiorentini C, Mattioli G, Casadei V, Guadagni S (2019) Modulated electrohyperthermia in integrative cancer treatment for relapsed malignant glioblastoma and astrocytoma: retrospective multicenter controlled study. Integr Cancer Ther. https:\/\/doi.org\/10.1177\/1534735418812691","journal-title":"Integr Cancer Ther"},{"key":"3900_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-019-03116-z","volume":"142","author":"A Silvani","year":"2019","unstructured":"Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D\u2019Incalci M (2019) Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. J Neurooncol 142:455\u2013462","journal-title":"J Neurooncol"},{"issue":"5","key":"3900_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10072-014-2025-9","volume":"6","author":"PF Jia","year":"2015","unstructured":"Jia PF, Gu WT, Zhang WF, Li F (2015) Treatment of recurrent malignant gliomas with 13-cis-retinoic acid naphthalene triazole. Neurol Sci 6(5):717\u2013721","journal-title":"Neurol Sci"},{"key":"3900_CR31","first-page":"309","volume":"126","author":"E Roci","year":"2014","unstructured":"Roci E, Cakani B, Brace G, Bushati T, Rroji A, Petrela M, Kaloshi G (2014) A randomized phase I\/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126:309\u2013316","journal-title":"J Neurooncol"},{"issue":"6","key":"3900_CR32","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3892\/ijo.2014.2382","volume":"44","author":"J Rieger","year":"2014","unstructured":"Rieger J, Bahr O, Maurer GD et al (2014) ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44(6):1843\u20131852","journal-title":"Int J Oncol"},{"key":"3900_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000440678","volume":"60","author":"M Tonder","year":"2014","unstructured":"Tonder M, Weller M, Eisele G, Roth P (2014) Carboplatin and etoposide in heavily pretreated patients with progressive high-grade glioma. Chemotherapy 60:375\u2013378","journal-title":"Chemotherapy"},{"key":"3900_CR34","first-page":"5625","volume":"33","author":"CO Da Fonseca","year":"2013","unstructured":"Da Fonseca CO, Teixeira RM, Silva JCT, Fisher JDG, Meirelles OC, Landeiro JA, Quirico-Santos T (2013) Long term outcome in patietns with recurrent malignat glioma treated with Perillyl Alcohol inhalation. Anticancer Res 33:5625\u20135631","journal-title":"Anticancer Res"},{"key":"3900_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11060-012-1023-0","volume":"111","author":"J Hu","year":"2013","unstructured":"Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F (2013) A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol 111:347\u2013353","journal-title":"J Neurooncol"},{"key":"3900_CR36","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T et al (2015) Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5:18046","journal-title":"Sci Rep"},{"issue":"24","key":"3900_CR37","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2017","unstructured":"Kirson ED, Dbal\u00fd V, Tovarys F et al (2017) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104(24):10152\u201310157","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3900_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fneur.2019.00042","volume":"10","author":"G Lu","year":"2019","unstructured":"Lu G, Rao M, Zhu P et al (2019) Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol 10:42","journal-title":"Front Neurol"},{"issue":"3","key":"3900_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2217\/cns-2016-0049","volume":"6","author":"S Kesari","year":"2017","unstructured":"Kesari S, Ram Z (2017) Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol 6(3):185\u2013193","journal-title":"CNS Oncol"},{"key":"3900_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000442196","volume":"8","author":"G Ansstas","year":"2016","unstructured":"Ansstas G, Tran DD (2016) Treatment with tumor-treating fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: a case series. Case Rep Neurol 8:1\u20139","journal-title":"Case Rep Neurol"},{"issue":"3","key":"3900_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/cam4.421","volume":"4","author":"ET Wong","year":"2015","unstructured":"Wong ET, Lok E, Swanson KD (2015) Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Med 4(3):383\u2013391","journal-title":"Cancer Med"},{"key":"3900_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1477-7819-10-220","volume":"10","author":"AM Rulseh","year":"2012","unstructured":"Rulseh AM, Keller J, Klener j J, et al (2012) Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol 10:220","journal-title":"World J Surg Oncol"},{"issue":"14","key":"3900_CR43","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (Oxford, England: 1990) 48(14):2192\u20132202","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"9","key":"3900_CR44","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.2174\/138920112800958814","volume":"13","author":"B Kaur","year":"2012","unstructured":"Kaur B, Chiocca EA, Cripe TP (2012) Oncolytic HSV-1 virotherapy: clinical experience and opportunity for progress. Curr Pharm Biotechnol 13(9):1842\u201351","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"3900_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/PPO.0b013e31824671c9","volume":"18","author":"G Wollman","year":"2012","unstructured":"Wollman G, Ozduman K, van den Pol A (2012) Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 18(1):69\u201381","journal-title":"Cancer J"},{"issue":"14","key":"3900_CR46","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C et al (2018) Phase I study of DNX-2401 (Delta-24-RGD) Oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36(14):1419\u20131427","journal-title":"J Clin Oncol"},{"issue":"12","key":"3900_CR47","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","volume":"25","author":"K Geletneky","year":"2017","unstructured":"Geletneky K, Hajda J, Angelova AL et al (2017) Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial. Mol Ther 25(12):2620\u20132634","journal-title":"Mol Ther"},{"issue":"341","key":"3900_CR48","doi-asserted-by":"publisher","first-page":"341re75","DOI":"10.1126\/scitranslmed.aad9784","volume":"8","author":"TF Cloughesy","year":"2016","unstructured":"Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA (2016) Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med 8(341):341re75","journal-title":"Sci Transl Med"},{"issue":"5","key":"3900_CR49","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2014.21","volume":"22","author":"KP Kicielinski","year":"2014","unstructured":"Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM (2014) Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 22(5):1056\u20131062 (Epub 2014 Feb 20)","journal-title":"Mol Ther"},{"key":"3900_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","volume":"17","author":"JM Markert","year":"2009","unstructured":"Markert JM, Liechty PG, Wang W et al (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17:199\u2013207","journal-title":"Mol Ther"},{"key":"3900_CR51","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth P, Roldan G, George D et al (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16:627\u2013632","journal-title":"Mol Ther"},{"issue":"1","key":"3900_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","volume":"13","author":"AI Freeman","year":"2006","unstructured":"Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13(1):221\u2013228","journal-title":"Mol Ther"},{"issue":"5","key":"3900_CR53","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","volume":"10","author":"EA Chiocca","year":"2004","unstructured":"Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10(5):958\u2013966","journal-title":"Mol Ther"},{"key":"3900_CR54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854\u2013856","journal-title":"Science"},{"key":"3900_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz219.1199","author":"T Cloughesy","year":"2019","unstructured":"Cloughesy T, Petrecca T, Walbert T et al (2019) LTBK-08. Toca 511 & Toca FC versus standard of care in patients with recurrent high grade glioma. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noz219.1199","journal-title":"Neuro Oncol"},{"key":"3900_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.wneu.2017.02.061","volume":"102","author":"L Stockelmaier","year":"2017","unstructured":"Stockelmaier L, Renovanz M, Konig J et al (2017) Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life. World Neurosurg 102:383\u2013399","journal-title":"World Neurosurg"},{"key":"3900_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-017-2534-5","volume":"134","author":"E Chang","year":"2017","unstructured":"Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, Gambhir SS (2017) Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. J Neurooncol 134:259\u2013268","journal-title":"J Neurooncol"},{"key":"3900_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now212.382","author":"T Holtzman","year":"2016","unstructured":"Holtzman T (2016) IMST-26 Tumor treating fields exposure of tumor cells induce activation phenotype in immune cells. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/now212.382","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03900-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T08:16:36Z","timestamp":1655367396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03900-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3900"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03900-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-827194\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Guideline Task Force members were required to disclose all potential COIs prior to beginning work on the guideline, using the COI disclosure form of the AANS\/CNS Joint Guidelines Review Committee. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination and participation on the task force. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of task force members with possible conflicts and restrict the writing, reviewing, and\/or voting privileges of that person to topics that are unrelated to the possible COIs. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this series of articles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}